Alexion CEO Says FDA's Strensiq Decision Due in Matter of Weeks

  • Treatment for ultra-rare bone disease approved in Europe
  • Drugmaker looking to expand beyond blockbuster Soliris

Alexion Pharmaceuticals Inc. said U.S. regulators are likely to decide in the next few weeks whether to approve Strensiq, its therapy for a rare genetic bone disease, after intensive discussions about the information included on the product’s label.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.